Navigation Links
New CDC Study Confirms Effectiveness of UV-C Disinfection in Reducing Harmful Pathogens for Hospitals
Date:4/19/2013

DURHAM, N.C., April 19, 2013 /PRNewswire/ -- A recent study funded by Centers for Disease Control and Prevention (CDC) Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.

It is well-documented that these pathogens, along with others such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE), can persist on environmental surfaces for days or weeks, and C. diff. spores can exist as long as five months on surfaces in hospital environments. Standard approaches to environmental cleaning have proven inadequate with studies showing that 50 percent or more of hospital surfaces go untouched during terminal room disinfection, leading to the transmission of these hardy pathogens from one patient to another. The data published by the Society of Healthcare Epidemiology of America (SHEA) concluded that an automated UV-C system capable of delivering a measured and consistent UV-C dose significantly improved terminal disinfection of patient areas in hospitals.

The only device utilized in the study is TRU-D SmartUVC™, a portable UV disinfection system unique to the market with Sensor360™ technology, which analyzes the unique contents, shape and size of the room to calculate the precise pathogen-lethal dose of UV-C light needed to properly disinfect the environment (both line-of-site and shadowed spaces). A proper dose of UV-C light modifies the DNA structure of an infectious cell so it cannot reproduce and therefore cannot colonize and spread. These results were confirmed by the study, which reported a significant decrease in the total number of colony-forming units (CFUs) of these pathogens in both direct and indirect line of sight.

"Results of TRU-D have been supported by multiple independent peer-reviewed studies conducted by leading authorities in infection control and epidemiology," said Chuck Dunn , president of Memphis-based Lumalier, maker of TRU-D SmartUVC. "We are pleased to add another reputable third-party validation of our method of automated no-touch disinfection."

The study was performed at two tertiary acute care hospitals, Duke University Medical Center and University of North Carolina Health Care, from July 2011 through September 2011. Hospital rooms utilized in the study were identified as those of patients placed on precautions as a result of colonization or infection with a target organism. Environmental cultures – from direct and indirect lines of site – were obtained on specific environmental locations within the room after patient discharge and before manual room cleaning by housekeeping personnel. TRU-D was then used in the room, and cultures were repeated in triplicate from the same environmental sites following application of the UV-C light. In total, 229 environmental surfaces were sampled in the rooms of 39 patients over the 15-month study. Following use of TRU-D, there was a calculated reduction of more than 91 percent in the total number of CFUs of any pathogen detected from all sampled sites. Additionally, a greater than 92-percent reduction was achieved for all three target organisms (97.89 percent for VRE, 92.95 percent for C. diff. and 98.07 percent for Acinetobacter), with no statistically significant differences in reductions occurring in direct versus indirect line of sight disinfection for any of these categories.

TRU-D SmartUVC™, the signature product of Memphis-based Lumalier, is the only portable UV disinfection system on the market that precisely measures reflected UVC emissions with Sensor360™ to automatically calculate the pathogen-lethal UV dose required for proper and consistent disinfection of health care environments. For information, visit www.TRU-D.com.

For more information, contact:
Kerri Guyton
Obsidian Public Relations
Phone: 662-422-8012
Email

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Lumalier
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... to 2025" report to their offering. ... The Global Cryostat Market is poised ... decade to reach approximately $3.5 billion by 2025. This ... given segments on global as well as regional levels presented in ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... Technique, Repair Procedure By Technique, By Region, By Country (2016-2021)" ... ... at a CAGR of 13.35% during 2016-2021 The strong ... growth in population with heart disease and rising advances in minimally ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge ... now offering treatments for sleep apnea and TMJ at their office. TMJ, or ... , specifically the obstructive type, is increasingly being treated at dental offices with ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... the year of enhancements, upgrading their training and leads programs. , In February, ... Reserved for elite sales agents, Performance Partners is designed to teach how to ...
(Date:3/24/2017)... ... ... “The Communion of Saints: A Pastor’s Potpourri of Parishioners”: ... the United States. “The Communion of Saints” is the creation of published ... in seven states throughout his long career of devotion to the church. In ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment ... more public health departments have been awarded national accreditation through the Public ... into the expanding network of communities across the nation whose health departments meet ...
Breaking Medicine News(10 mins):